JAMA Study Endorses Standard Amoxicillin as the Primary Antibiotic Treatment for Uncomplicated Acute Sinusitis

New 2026 study in JAMA confirms standard amoxicillin is the top choice for adult acute sinusitis. Learn why narrow-spectrum antibiotics are the better option.

By: AXL Media

Published: Apr 18, 2026, 11:10 AM EDT

Source: Information for this report was sourced from JAMA

Clinical Preference Established for Common Respiratory Infection

New research published in the Journal of the American Medical Association (JAMA) has clarified the hierarchy of treatment for adults suffering from uncomplicated acute sinusitis. The study, led by corresponding author Timothy J. Savage of Mass General Brigham, formally supports the use of standard-dose amoxicillin as the primary empiric choice for patients under the age of 65. This recommendation addresses a long-standing debate within the medical community regarding whether more powerful, combination antibiotics are necessary for routine cases.

Evidence-Based Selection Criteria for Adult Patients

The investigation focused specifically on cases where a medical professional has already determined that an antibiotic intervention is indicated. By isolating uncomplicated instances of the condition, the researchers were able to demonstrate that the added chemical complexity of combination drugs like amoxicillin-clavulanate does not offer a significant clinical advantage in this demographic. This finding is particularly relevant for primary care physicians who must balance effective symptom resolution with the broader public health goal of prudent antibiotic stewardship.

Presentation at Global Infectious Disease Congress

The details of this significant study were unveiled to the international medical community during the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026 congress. This venue serves as a major platform for disseminating high-impact clinical data that influences global prescribing standards. The presentation highlighted that for the majority of the adult population, the risks associated with broader-spectrum medications can be avoided without sacrificing the quality of care or the speed of recovery.